Moderna (NASDAQ:MRNA) Price Target Raised to $151.00 at UBS Group

Moderna (NASDAQ:MRNA) had its price objective lifted by analysts at UBS Group from $143.00 to $151.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s target price suggests a potential upside of 23.88% from the company’s current price.

Other research analysts have also recently issued reports about the stock. Royal Bank of Canada lifted their price target on shares of Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. HSBC reiterated a “reduce” rating and set a $86.00 target price (up from $75.00) on shares of Moderna in a report on Monday, February 26th. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Oppenheimer lifted their price objective on Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $126.89.

Moderna Stock Up 0.7 %

MRNA stock opened at $121.89 on Tuesday. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $142.79. The company has a market capitalization of $46.71 billion, a price-to-earnings ratio of -7.78 and a beta of 1.57. The business’s 50 day moving average price is $106.59 and its two-hundred day moving average price is $95.24. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The firm’s revenue for the quarter was down 91.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.19 earnings per share. As a group, analysts forecast that Moderna will post -7.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total value of $1,663,800.00. Following the completion of the sale, the director now directly owns 2,026,931 shares in the company, valued at $224,827,186.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the transaction, the director now directly owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Shannon Thyme Klinger sold 670 shares of Moderna stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $63,361.90. Following the completion of the sale, the insider now directly owns 8,557 shares of the company’s stock, valued at approximately $809,235.49. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 139,954 shares of company stock worth $14,822,576. Company insiders own 15.20% of the company’s stock.

Hedge Funds Weigh In On Moderna

Several institutional investors have recently made changes to their positions in MRNA. Ogorek Anthony Joseph NY ADV purchased a new stake in Moderna during the fourth quarter valued at approximately $27,000. Arlington Trust Co LLC boosted its stake in shares of Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after acquiring an additional 290 shares during the last quarter. Westside Investment Management Inc. bought a new stake in shares of Moderna during the 1st quarter valued at $32,000. Rise Advisors LLC increased its stake in shares of Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after purchasing an additional 286 shares in the last quarter. Finally, UMB Bank n.a. raised its holdings in Moderna by 121.8% in the 1st quarter. UMB Bank n.a. now owns 366 shares of the company’s stock worth $39,000 after purchasing an additional 201 shares during the period. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.